Clinical Trial: Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07924059) titled 'Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia' on Oct. 30.

Brief Summary: This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Achondroplasia

Intervention: DRUG: Dual therapy with navepegritide and lonapegsomatropin

Administered weekly as two separate SC injections. Treatment dura...